Canntab Therapeutics Limited (CTABF)
Canntab Therapeutics Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Markham, ON, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3,891. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -1257.6%. Its beta of 1.42 implies it has historically moved more than the broad market.
Canntab Therapeutics Limited, a phytopharmaceutical firm with its main office in Markham, Canada, is dedicated to the research and development of sophisticated, medical-grade cannabinoid compounds. The company's diverse portfolio within Canada includes various orally administered pharmaceutical cannabis products. These innovative dosage forms encompass extended-release cannabinoid pellets, rapid-onset cannabidiol options, multi-layered modified-release formulations, quickly dissolving flash-melt versions, and dual-layer cannabinoid tablets. Canntab's products are designed to address a wide spectrum of health concerns, such as sleep disturbances, post-traumatic stress disorder, social anxiety, different forms of addiction, arthritic conditions, general pain management, alleviating pain and stimulating appetite for cancer patients, and aiding in recovery from opioid and other painkiller dependencies.
Canntab Therapeutics Limited is most often compared with the following Healthcare names: